Terumo BCT and Terumo Corporation, our parent company, are actively responding to the current outbreak of coronavirus disease (COVID-19). This includes focusing on the health and safety of our employees, maintaining a strong product supply, growing our external research program, and leveraging our resources and technologies in the fight against COVID-19. In all cases, our response is guided by our mission: Contributing to Society Through Healthcare.
Our utmost priority is the continued health and well-being of our 7,100 employees worldwide.
Learn how we are actively engaged in and contributing to the global efforts for the prevention and treatment of COVID-19.
People who have recovered from a virus like COVID-19 have antibodies to the disease in their blood. Through a simple transfusion process, those same antibodies can be shared with others who have the virus so they, too, can better fight the disease.
Read More
A new study shows Terumo BCT's Mirasol Pathogen Reduction Technology (PRT) System is effective against the virus that causes COVID-19 when high virus levels are present in human plasma and platelets. This system is designed to add an extra layer of safety to the blood supply.1
A study is underway to show how Terumo's Spectra Optia® Apheresis System and Marker Therapeutics Depuro D2000 Adsorption Cartridges can reduce cytokine storms in COVID-19 patients' blood.2
Watch Now
What is convalescent plasma? And is it effective in fighting COVID-19?
System Combines Terumo BCT and Marker Therapeutics AG devices to help severely ill COVID-19 patients
This International Society of Blood Transfusion (ISBT) corporate partner education webinar features Michael Schmidt, Raymond Goodrich & Marcia Cardoso.
Vox Sanguinis, a peer-reviewed medical journal, published results from a Terumo BCT study conducted in collaboration with top researchers at Colorado State University. The study examined how well the Mirasol system treated platelets and plasma against the virus causing COVID-19.
Terumo Corporation is donating USD 2.4 million in cash and products to support the novel coronavirus disease relief efforts worldwide – including a USD 1 million donation to the COVID-19 Solidarity Response Fund for WHO.
“We thank the Food and Drug Administration for their expedited review, which provides another treatment option for patients in the ICU to help reduce the severity of the disease,” says Antoinette Gawin, CEO and President of Terumo BCT, and David Cohen, Chairman of Marker.
1The Mirasol PRT system is not approved for sale in the U.S.
2FDA Required Disclaimers:
We are exercising maximum effort to maintain a stable supply of products to meet healthcare needs.
Terumo BCT has a comprehensive and established Business Continuity Policy in place, designed to safeguard our associates around the world and our ability to deliver products worldwide.
Terumo BCT has strong business continuity plans to help ensure continued availability of our products that are used to treat critically ill patients and that collect and process blood and blood products. We know a safe, sustainable and readily available supply of blood is vital to those with serious conditions and diseases.
Discovery never stops. We share a passion for thinking in new and different ways and support COVID-19 studies around the globe with scientific and medical merit developed by independent investigators or academic sponsors around the globe. Visit our External Research Program (ERP) for more information.